ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
1541
Pozycja w akcjach
#19271
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Cena akcji
$0.37738238
Kapitalizacja rynkowa
$158.14M
Zmiana (1 dzień)
-1.01%
Zmiana (1 rok)
-72.00%
Kraj
CN
Handel ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
Kategoria
Healthcare
EPS dla ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
EPS na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji firmy ImmuneOnco Biopharmaceuticals (Shanghai) Inc., obecny EPS (TTM) wynosi 0. Na koniec roku 2026 firma miała EPS w wysokości 0, równa się do EPS z roku 2026, który wynosił 0.
Historia EPS dla ImmuneOnco Biopharmaceuticals (Shanghai) Inc. od 2026 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| Za mało danych dla podanych dat. | ||
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| - | - |
CH
|
|
| $27.74 | - |
NL
|
